NRXN1 as a Prognostic Biomarker: Linking Copy Number Variation to EMT and Survival in Colon Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Copy number deletion of NRXN1 is a promising biomarker for predicting recurrence and survival in colorectal cancer (CRC) patients. Lower NRXN1 expression suggests a tumor suppressor role, impacting cancer progression and invasion.
Area Of Science
- Oncology
- Genetics
- Molecular Biology
Background
- Biomarker roles in cancer treatment are stage-dependent, necessitating tailored approaches for precision medicine.
- Copy number variation (CNV) biomarkers reflect genetic alterations and are crucial for cancer prognosis.
- Previous research identified potential survival-related genes in colorectal cancer (CRC) using CNV and gene expression data.
Purpose Of The Study
- To investigate the biological function of NRXN1 in colorectal cancer.
- To assess NRXN1 copy number variation as a prognostic biomarker for CRC patients.
Main Methods
- RNA sequencing
- Phosphokinase assays
- Real-time quantitative PCR
- Western blot analysis
- Transcriptome analysis
Main Results
- NRXN1 copy number deletion significantly correlated with poor overall survival (OS) and recurrence-free survival (RFS) in CRC patients, irrespective of adjuvant chemotherapy.
- NRXN1 expression was reduced in tumors compared to normal tissues, indicating a potential tumor suppressor function.
- NRXN1 knockdown increased CRC cell viability and invasion, mediated by GSK3β-dependent epithelial-mesenchymal transition.
Conclusions
- NRXN1 copy number deletion is a novel and significant biomarker for predicting recurrence and survival in patients with resected colon cancer.
- NRXN1's tumor-suppressive role and its association with epithelial-mesenchymal transition provide insights into CRC progression.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.